The European journal of cardiovascular medicine最新文献

英文中文

Short, Intermediate and long term outcomes of CABG vs. PCI with DES in Patients With Multivessel Coronary Artery Disease. Meta-Analysis of Six Randomized Controlled Trials. 冠状动脉多支病变患者冠脉搭桥与PCI联合DES的短期、中期和长期预后六项随机对照试验的荟萃分析。

The European journal of cardiovascular medicine

Pub Date : 2014-09-08

Zaher Fanari, Sandra A Weiss, Wei Zhang, Seema S Sonnad, William S Weintraub

Objective: Comparing outcomes of percutaneous coronary intervention (PCI) with drug eluting stent (DES) and Coronary Artery Bypass Grafting (CABG) in patients with multivessel Coronary Artery Disease (CAD) using data from randomized controlled trials (RCT).

Background: PCI and CABG are established strategies for coronary revascularization in the setting of ischemic heart disease. Multiple RCT have compared outcomes of the two modalities in patients with multivessel CAD.

Methods: We did a meta-analysis from six RCT in the contemporary era comparing the effectiveness of PCI with DES to at 1 year, 2 years and 5 years respectively.

Results: Compared to CABG, at one year PCI was associated with a significantly higher incidence of TVR (RR= 2.31; 95% CI: [1.80 - 2.96]; P=<0.0001), lower incidence of stroke (RR= 0.35; 95% CI: [0.19 - 0.62]; P=0.0003), and no difference in death (RR= 1.02; 95% CI: [0.77 - 1.36]; P= 0.88) or MI (RR= 1.16; 95% CI: [0.72 - 1.88]; P= 0.53). At 5 years, PCI was associated with a higher incidence of death (RR= 1.3; 95% CI: [1.10 - 1.54]; P= 0.0026) and MI (RR= 2.21; 95% CI: [1.75 - 2.79]; P=<0.0001). While the higher incidence of MI with PCI was noticed in both diabetic and non-diabetics, death was increased mainly in diabetic patients.

Conclusion: In patients with multi-vessel CAD, PCI with DES is associated with no significant difference in death or MI at 1 or 2 years. However at 5 years, PCI is associated with higher incidence of death and MI.

目的:采用随机对照试验(RCT)比较经皮冠状动脉介入治疗(PCI)联合药物洗脱支架(DES)与冠状动脉旁路移植术(CABG)治疗多支冠状动脉疾病(CAD)的疗效。背景:在缺血性心脏病的情况下，PCI和CABG是冠状动脉血运重建的既定策略。多项随机对照试验比较了两种治疗方式在多血管冠心病患者中的疗效。方法:我们对当代6项随机对照试验进行荟萃分析，比较PCI与DES分别在1年、2年和5年的疗效。结果:与CABG相比，一年后PCI与TVR的发生率显著升高(RR= 2.31;95% ci: [1.80 - 2.96];P=结论:在多血管CAD患者中，PCI + DES与1年或2年的死亡或心肌梗死无显著差异。然而，在5年时，PCI与较高的死亡和心肌梗死发生率相关。

{"title":"Short, Intermediate and long term outcomes of CABG vs. PCI with DES in Patients With Multivessel Coronary Artery Disease. Meta-Analysis of Six Randomized Controlled Trials.","authors":"Zaher Fanari, Sandra A Weiss, Wei Zhang, Seema S Sonnad, William S Weintraub","doi":"","DOIUrl":"","url":null,"abstract":"Objective: Comparing outcomes of percutaneous coronary intervention (PCI) with drug eluting stent (DES) and Coronary Artery Bypass Grafting (CABG) in patients with multivessel Coronary Artery Disease (CAD) using data from randomized controlled trials (RCT).Background: PCI and CABG are established strategies for coronary revascularization in the setting of ischemic heart disease. Multiple RCT have compared outcomes of the two modalities in patients with multivessel CAD.Methods: We did a meta-analysis from six RCT in the contemporary era comparing the effectiveness of PCI with DES to at 1 year, 2 years and 5 years respectively.Results: Compared to CABG, at one year PCI was associated with a significantly higher incidence of TVR (RR= 2.31; 95% CI: [1.80 - 2.96]; P=<0.0001), lower incidence of stroke (RR= 0.35; 95% CI: [0.19 - 0.62]; P=0.0003), and no difference in death (RR= 1.02; 95% CI: [0.77 - 1.36]; P= 0.88) or MI (RR= 1.16; 95% CI: [0.72 - 1.88]; P= 0.53). At 5 years, PCI was associated with a higher incidence of death (RR= 1.3; 95% CI: [1.10 - 1.54]; P= 0.0026) and MI (RR= 2.21; 95% CI: [1.75 - 2.79]; P=<0.0001). While the higher incidence of MI with PCI was noticed in both diabetic and non-diabetics, death was increased mainly in diabetic patients.Conclusion: In patients with multi-vessel CAD, PCI with DES is associated with no significant difference in death or MI at 1 or 2 years. However at 5 years, PCI is associated with higher incidence of death and MI.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"3 1","pages":"382-389"},"PeriodicalIF":0.0,"publicationDate":"2014-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234175/pdf/nihms-639457.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32828282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

QTc and QTd Changes after Cardiopulmonary Bypass Surgery in Children 儿童体外循环手术后QTc和QTd的变化

The European journal of cardiovascular medicine

Pub Date : 2014-02-01 DOI: 10.5083/EJCM.20424884.110

E. Aburawi, A. Souid, P. Liuba, E. Pesonen

The aim of the study was to assess the impact of cardiopulmonary bypass surgery on corrected QT (QTc) and QT dispersion (QTd) intervals. The possible role of inflammation on these variables was investigated.

本研究的目的是评估体外循环手术对校正QT (QTc)和QT离散度(QTd)间期的影响。研究了炎症对这些变量的可能作用。

引用次数: 0

Delayed Statin Treatment Reduces the Cardioprotective Effects on Congestive Heart Failure after Acute Myocardial Infarction 延迟他汀类药物治疗降低急性心肌梗死后充血性心力衰竭的心脏保护作用

The European journal of cardiovascular medicine

Pub Date : 2014-02-01 DOI: 10.5083/ejcm.20424884.107

Tsuyoshi Honda, K. Fujimoto, Y. Miyao, Hidenobu Koga, M. Ishii

引用次数: 0

The Value of Simplified Selvester QRS Scoring System in Predicting ST-segment Resolution after Thrombolysis in Patients with Acute Myocardial Infarction 简化Selvester QRS评分系统预测急性心肌梗死患者溶栓后st段溶解的价值

The European journal of cardiovascular medicine

Pub Date : 2014-02-01 DOI: 10.5083/EJCM.20424884.108

S. Ghaffari, B. Kazemi, Gholamreza Saeidi, N. Sepehrvand, L. Pourafkari

引用次数: 0

Multiple Coronary–Cameral Fistulae in the Left Anterior Descending Coronary Artery Causing Angina Pectoris: A Clinical Case and the State of the Art 左冠状动脉前降支多发冠状-摄膜瘘致心绞痛:1例临床及最新研究进展

The European journal of cardiovascular medicine

Pub Date : 2014-02-01 DOI: 10.5083/EJCM.20424884.111

G. Musuraca, R. Albiero, C. Terraneo, E. Boldi, C. Angheben

引用次数: 0

Identifying Heart Valve Disease In Primary Care: Differences Between Practice In Germany, France And The United Kingdom 在初级保健中识别心脏瓣膜疾病:德国、法国和英国实践的差异

The European journal of cardiovascular medicine

Pub Date : 2014-01-01 DOI: 10.5083/EJCM.20424884.124

J. Webb, Martin Theones, J. Chambers

引用次数: 12

ACE I/D and ADD1 Polymorphisms in Individuals with Cardiovascular Diseases: Prospects on Risk Assessment and Pharmacogenetics 心血管疾病患者ACE I/D和ADD1多态性:风险评估和药物遗传学研究前景

The European journal of cardiovascular medicine

Pub Date : 2013-12-01 DOI: 10.5083/EJCM.20424884.106

R. M. Guia, F. Aguirre, Angeli Kaye M. Calderon, H. Gamboa, L. Ching, B. Madamba, L. Mangahas, Ma. Victoria P. Policina, R. R. Santos, J. A. Serrano, Bob Brain O. Sotingco, Earl Louis Sempio, M. G. Gabona

引用次数: 0

Pericardial Abscess with Tamponade Caused by S. Enteritidis Infection 肠炎沙门氏菌感染致心包脓肿伴填塞

The European journal of cardiovascular medicine

Pub Date : 2013-12-01 DOI: 10.5083/EJCM.20424884.105

P. Artemiou, Frantisek Sabo, B. Bílý, V. Kováčová, D. Ondušová

This is a case report which is describing a 54 years old female who complained of dyspnea and diarrhea and was found to have S. enteritidis pericardial abscess causing compression of the right atrium and ventricle resulting in cardiac tamponade. She was treated with surgery and antibiotics and survived. Pericardial Abscess with Tamponade Caused by S. Enteritidis Infection CARDIAC TAMPONADE | CASE REPORT

这是一个病例报告，描述了一个54岁的女性，她抱怨呼吸困难和腹泻，被发现有肠炎沙门氏菌心包脓肿，导致右心房和心室受压，导致心脏填塞。她接受了手术和抗生素治疗，活了下来。肠炎沙门氏菌感染致心包脓肿合并心包填塞60例报告

引用次数: 0

Hearing Loss Due to Familial Hypercholesterolemia and Statin Treatment 家族性高胆固醇血症引起的听力损失和他汀类药物治疗

The European journal of cardiovascular medicine

Pub Date : 2013-10-01 DOI: 10.5083/EJCM.20424884.104

M. Oylumlu, Faris M. Lolan, S. Ercan, G. Altunbas, Z. Karataş, V. Davutoglu

引用次数: 1

Cardiometabolic interventions - focus on transcriptional regulators. 心脏代谢干预--关注转录调节因子。

The European journal of cardiovascular medicine

Pub Date : 2013-08-13 DOI: 10.5083/ejcm.20424884.102

Joshua T Chai, Robin P Choudhury

Cardiovascular disease (CVD) remains the largest healthcare burden in the Western world; and the increasing prevalence of type II diabetes mellitus, at least partially driven by a trend in lifestyle changes associated with global economic development, is likely to fuel this CVD burden worldwide. Over the past two decades, there has been an increased awareness of the convergence of risk factors contributing to both cardiovascular disease and diabetes leading to the concept of the metabolic syndrome, and the realisation of the opportunity to intervene at this intersection to simultaneously target CVD and metabolic dysfunction. This brings together the fields of cardiovascular medicine, diabetology, and increasingly clinical immunology for a unified and concerted effort to reduce risk for both conditions simultaneously. The discovery of the targeted pathways of drugs already in clinical use such as fibrates and thiazolidinediones (TZD) has led to accelerated basic and clinical research into selective and dual PPAR-α and PPAR-γ agonists, which can theoretically target glucose, lipid and lipoprotein metabolism, as well as potentially exerting inhibitoryeffects in vascular inflammation, all of which might be predicted to reduce atherosclerosis. In this article, we will discuss the basic science as well as recent clinical development in the pursuit of optimal cardiometabolic intervention along with insight into strategies for future drug development.

心血管疾病（CVD）仍然是西方世界最大的医疗负担；而 II 型糖尿病患病率的上升（至少部分原因是与全球经济发展相关的生活方式改变趋势）很可能会加重全球的心血管疾病负担。在过去的二十年里，人们越来越意识到导致心血管疾病和糖尿病的风险因素趋于一致，从而产生了代谢综合征的概念，并意识到有机会在这一交叉点上进行干预，以同时解决心血管疾病和代谢功能障碍问题。这就将心血管医学、糖尿病学以及越来越多的临床免疫学领域结合在一起，为同时降低这两种疾病的风险做出统一而协调的努力。由于发现了纤维酸盐和噻唑烷二酮类（TZD）等已在临床上使用的药物的靶向途径，加速了对选择性和双重 PPAR-α 和 PPAR-γ 激动剂的基础和临床研究，这些药物理论上可以靶向葡萄糖、脂质和脂蛋白代谢，并可能对血管炎症产生抑制作用，所有这些都可望减少动脉粥样硬化。在本文中，我们将讨论在追求最佳心脏代谢干预方面的基础科学和最新临床发展，并深入探讨未来药物开发的策略。

{"title":"Cardiometabolic interventions - focus on transcriptional regulators.","authors":"Joshua T Chai, Robin P Choudhury","doi":"10.5083/ejcm.20424884.102","DOIUrl":"10.5083/ejcm.20424884.102","url":null,"abstract":"Cardiovascular disease (CVD) remains the largest healthcare burden in the Western world; and the increasing prevalence of type II diabetes mellitus, at least partially driven by a trend in lifestyle changes associated with global economic development, is likely to fuel this CVD burden worldwide. Over the past two decades, there has been an increased awareness of the convergence of risk factors contributing to both cardiovascular disease and diabetes leading to the concept of the metabolic syndrome, and the realisation of the opportunity to intervene at this intersection to simultaneously target CVD and metabolic dysfunction. This brings together the fields of cardiovascular medicine, diabetology, and increasingly clinical immunology for a unified and concerted effort to reduce risk for both conditions simultaneously. The discovery of the targeted pathways of drugs already in clinical use such as fibrates and thiazolidinediones (TZD) has led to accelerated basic and clinical research into selective and dual PPAR-α and PPAR-γ agonists, which can theoretically target glucose, lipid and lipoprotein metabolism, as well as potentially exerting inhibitoryeffects in vascular inflammation, all of which might be predicted to reduce atherosclerosis. In this article, we will discuss the basic science as well as recent clinical development in the pursuit of optimal cardiometabolic intervention along with insight into strategies for future drug development.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"2 3","pages":"212-218"},"PeriodicalIF":0.0,"publicationDate":"2013-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769682/pdf/emss-54521.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

The European journal of cardiovascular medicine

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀